Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Endocrinology

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/en.2009-0295PMID 19497974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide-2 increases mesenteric blood flow in humans

  2009influential reference
• Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis

  2009influential reference
• Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.

  2009cited by this paper
• Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection.

  2009cited by this paper
• Mouse models for the study of colon carcinogenesis.

  2008influential reference
• Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.

  2008influential reference
• Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.

  2008cited by this paper
• Colorectal cancer and dysplasia in inflammatory bowel disease.

  2008influential reference
• Glucagon-Like Peptide-2 Activates β-Catenin Signaling in the Mouse Intestinal Crypt: Role of Insulin-Like Growth Factor-I

  2008influential reference
• Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects

  2008influential reference
• Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat.

  2007cited by this paper
• Disrupting insulin-like growth factor signaling as a potential cancer therapy

  2007cited by this paper
• Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators.

  2007influential reference
• The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.

  2006influential reference
• GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.

  2006cited by this paper
• IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment

  2006cited by this paper
• Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease

  2006influential reference
• beta-Catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice.

  2006cited by this paper
• Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet.

  2005influential reference
• Mucin‐depleted foci have β‐catenin gene mutations, altered expression of its protein, and are dose‐ and time‐dependent in the colon of 1,2‐dimethylhydrazine‐treated rats

  2005cited by this paper
• Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

  2005influential reference
• GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.

  2005cited by this paper
• Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

  2005influential reference
• Biologic actions and therapeutic potential of the proglucagon-derived peptides

  2005influential reference
• An unusual case of abdominal pain

  2004influential reference
• Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

  2004influential reference
• Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis.

  2003influential reference
• Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis.

  2003cited by this paper
• Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors.

  2003influential reference
• GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1.

  2003influential reference
• The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.

  2002influential reference
• Overexpression of the insulin‐like growth factor I receptor in human colon carcinomas

  2002cited by this paper
• Most Effective Colon Cancer Chemopreventive Agents in Rats: A Systematic Review of Aberrant Crypt Foci and Tumor Data, Ranked by Potency

  2002cited by this paper
• Modulation of specific intestinal epithelial progenitors by enteric neurons

  2001cited by this paper
• In vivo and in vitro degradation of glucagon-like peptide-2 in humans.

  2000influential reference
• Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.

  2000cited by this paper
• Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats.

  2000cited by this paper
• Distinctive Effects of Glicentin, GLP‐1 and GLP‐2 on Adaptive Response to Massive Distal Small Intestine Resection in Rats

  2000influential reference
• Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse

  2000influential reference
• Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine.

  2000cited by this paper
• Dysregulated expression of β-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice

  1999cited by this paper
• RESPONSE: Re: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3.

  1999cited by this paper
• Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

  1999cited by this paper
• Normal growth and development in the absence of hepatic insulin-like growth factor I.

  1999cited by this paper
• Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3

  1999cited by this paper
• Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.

  1997influential reference
• Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2.

  1997influential reference
• Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2.

  1997influential reference
• Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV

  1997cited by this paper
• Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

  1996cited by this paper
• MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.

  1996influential reference
• N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts.

  1995influential reference
• Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings.

  1987influential reference
• Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine.

  1973influential reference

• Successful Weaning from Continuous Parenteral Support with the Use of Teduglutide in a Patient with Short Bowel Syndrome: A Case Report

  2025cites this paper
• Determinación de la expresión de GLP-2 y GLP-2R en adenocarcinoma colorrectal

  2025cites this paper
• NEUROENDOCRINE PEPTIDES IN THE PATHOGENESIS OF COLORECTAL CARCINOMA.

  2023cites this paper
• GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells

  2022cites this paper
• Case Report: Morphologic and Functional Characteristics of Intestinal Mucosa in a Child With Short Bowel Syndrome After Treatment With Teduglutide: Evidence in Favor of GLP-2 Analog Safety

  2022cites this paper
• The Regulatory Role of Neuropeptide Gene Glucagon in Colorectal Cancer: A Comprehensive Bioinformatic Analysis

  2022cites this paper
• Glucagon-Like Peptide-2 Stimulates S-Phase Entry of Intestinal Lgr5+ Stem Cells

  2022cites this paper
• Teduglutide in short bowel syndrome patients: A way back to normal life?

  2021cites this paper
• Complementary and antagonistic effects of combined glucagon-like peptide-2 and glucagon-like peptide-1 receptor agonist administration on parameters relevant to short bowel syndrome.

  2021cites this paper
• Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors

  2021cites this paper
• De Novo Development of Distal Jejunal and Duodenal Adenomas after 41 Months of Teduglutide Treatment in a Short Bowel Patient: A Case Report.

  2020cites this paper
• Teduglutide Therapy in Two Patients With Short Bowel Syndrome and Familial Adenomatous Polyposis.

  2020cites this paper
• Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice

  2020cites this paper
• Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature.

  2019cites this paper
• Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.

  2019cites this paper
• The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia.

  2018cites this paper
• Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function.

  2018cites this paper
• Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions.

  2018cites this paper
• Glucagon like peptide-2 and neoplasia; a systematic review

  2018influential citation
• Role of Incretin Axis in Inflammatory Bowel Disease

  2017cites this paper
• Risk of Intestinal Malignancy in Patients With Short Bowel Syndrome

  2017cites this paper
• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet.

  2017cites this paper
• New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration

  2017cites this paper
• Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues

  2017cites this paper
• Glucagon‐like petide‐2 acts on colon cancer myofibroblasts to stimulate proliferation, migration and invasion of both myofibroblasts and cancer cells via the IGF pathway

  2017cites this paper
• Gastrointestinal Tract and Endocrine System

  2016cites this paper
• Current and potential therapeutic targets of glucagon-like peptide-2.

  2016cites this paper
• Glucagon-Like Peptide-2 Requires a Full Complement of Bmi-1 for Its Proliferative Effects in the Murine Small Intestine.

  2016cites this paper
• GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity.

  2016cites this paper
• Generation of glucagon‐like peptide‐2‐expressing Saccharomyces cerevisiae and its improvement of the intestinal health of weaned rats

  2016cites this paper
• The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice.

  2016cites this paper
• Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet

  2016cites this paper
• GLP‐2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet

  2015cites this paper
• GLP-2: what do we know? What are we going to discover?

  2014cites this paper
• A multidisciplinary approach to short bowel syndrome.

  2014cites this paper
• Growth hormone in the clinical management of the short bowel syndrome in a pig model

  2014cites this paper
• The effect of glucagon-like peptide-2 and intraluminal nutrients on intestinal adaptation in a rat model of short bowel syndrome

  2014cites this paper
• Short Bowel Syndrome in Childhood

  2014cites this paper
• Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.

  2014cites this paper
• Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs.

  2014cites this paper
• Review article: a comparison of glucagon‐like peptides 1 and 2

  2013cites this paper
• Teduglutide for the treatment of short bowel syndrome.

  2013cites this paper
• Glucagon-like peptide 2 in colon carcinogenesis: possible target for anti-cancer therapy?

  2013cites this paper
• Teduglutide Enhances Structural Adaptation of the Small Intestinal Mucosa in Patients With Short Bowel Syndrome

  2013influential citation
• Mechanisms of Glucagon-like Peptide-2-mediated Effects on Intestinal Barrier Function in Health and Irinotecan-induced Enteritis

  2013cites this paper
• AUTHOR COPY ONLY Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet

  2013cites this paper
• Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.

  2013influential citation
• A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists.

  2013cites this paper
• Role of Glucagon-like Peptide-2 in Rodent Models of Colon Cancer

  2012influential citation
• Bowel Syndrome : Every Night Without Parenteral Fluids

  2012cites this paper
• Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night.

  2012cites this paper
• Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

  2012cites this paper
• Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.

  2012cites this paper
• GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn's disease.

  2012cites this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

  2012cites this paper
• The Role of the GLP-2 Receptor in Intestinal and Islet Adaptation to Changes in Nutrient Availability

  2011cites this paper
• Glucagon-like peptide-2（GLP-2）と小腸の消化・吸収

  2011cites this paper
• Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.

  2011cites this paper
• Efficacy of the glucagon‐like peptide‐1 agonist exenatide in the treatment of short bowel syndrome

  2011cites this paper
• Emerging treatment options for short bowel syndrome: potential role of teduglutide

  2011cites this paper
• The "cryptic" mechanism of action of glucagon-like peptide-2.

  2011cites this paper
• Emerging treatment options for short bowel syndrome: potential role of teduglutide

  2011cites this paper
• Emerging treatment options for short bowel syndrome: potential role of teduglutide

  2011cites this paper
• The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease

  2011cites this paper
• The Effect of Glucagon-like Peptide-2 on Insulin-like Growth Factor-1 in Murine Intestinal Subepithelial Myofibroblasts

  2010cites this paper
• Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

  2010cites this paper
• The use of GLP-2 and related growth factors in intestinal diseases.

  2010cites this paper
• Clinical and Experimental Gastroenterology Dovepress Emerging Treatment Options for Short Bowel Syndrome: Potential Role of Teduglutide

  year unknowncites this paper